V Foundation
Pediatric Cancer Research-Immunology or Immunotherapy
Limited funding opportunity for Stanford faculty with UTL, MCL, and NTLR appointments and CE faculty (with an approved CE faculty PI waiver obtained through their RPM at least one-week prior to the internal deadline). Proposals will be accepted for preclinical research/translational research that supports new approaches to immunotherapy and immune-prevention of cancer, specifically in pediatric cancer research.
Timeline
- Stanford Cancer Institute internal deadline (one page proposal): Thursday, May 19, 2017, 5 p.m.
- Cancer Institute will notify the applicant selected: May 30, 2017.
- Cancer Institute will submit the Lead PI's Letter of intent, the LOI cover form & nomination forrm* to the foundation: June 2, 2017, 5 p.m. EDT *to be signed by Dr. Beverly Mitchell, the Director of the Cancer Institute.
- The foundation will then send the login credientials for the application system to the applicant.
- Completed PDRF form and complete application materials must be submitted to the applicant's RPM: July 8, 2017
- Online application to be submitted to the V Foundation: July 15, 2017
Amount of funding
The Award is a three-year grant of $200,000 per year. A maximum of 10% indirect costs (within the award amount) are supported in the Award. NIH salary caps are observed.
Eligibility
Nominated applicants who will lead the research team must meet all of the following criteria to be eligible to submit an application:
- The nominee must be nominated by their Cancer Center Director if the research institution is a cancer center
- Applicant must be employed at a US non-profit research institution (e.g. 501c3, Section 170).
- By the Due Date of the Application (July 15, 2017), applicants who will lead this research team must have all the following:
- Be scientists who hold a faculty position** at their cancer research institution. Non-promotable, adjunct, affiliated, temporary, part-time or acting faculty positions are not eligible for Principal Investigator nomination to lead the Translational Research Team.
- Stanford eligibility clarification: The lead PI must be a faculty member with UTL, MCL, NTLR or CE faculty** appointment.
- **CE faculty must obtain an approved CE faculty PI waiver request >> through their RPM at least one week prior to the internal deadline and include a copy with their internal proposal.)
- Not eligible: Instructors, Clinical Instructors, Academic staff-research (i.e., senior research scientists) are not eligible because Stanford does not consider those positions to be independent or faculty-level appointments.
- See the purpose that includes the areas of interest below
- Applicants must be either US Citizens or have a legal permit to work in the USA (either temporary or permanent).
Purpose
The V Foundation is pleased to announce a new grant opportunity in pediatric cancer immunology or pediatric cancer immunotherapy. Advances in cancer immunology research have led to recent unprecedented successes of immunotherapy in the clinic. We are seeking proposals that will further advance knowledge on the mechanisms driving anti-cancer immunity, including work on tumor antigens, immune biomarkers and the tumor immune microenvironment which may have future translational value.
We welcome proposals of preclinical research/translational research that supports new approaches to immunotherapy and immune-prevention of cancer, specifically in pediatric cancer research. We are interested in various immunotherapy/ cancer immunology research questions as applied to pediatric cancer, including: biomarker research for stratification, biomarker validation research, combination of checkpoint inhibitors with vaccines. We encourage cross disciplinary research, including expertise from other disciplines (for example: bioinformatics, computational scientists, or engineers) as applicable to the research. Grants will be awarded through the Translational Award grant mechanism.
Translational projects should move a novel strategy from the laboratory into a human clinical trial or use specimens from a clinical trial to develop biomarkers or mechanisms. The research should apply in some direct way to human beings within the time frame of less than 5 years. If biomarker research is undertaken, a validation set or independent clinical trial is essential. A plan for biomarker validation, if applicable, must be included in any proposal. The endpoint of the project should be the planning or initiation of a new clinical trial.
INTERNAL SUBMISION GUIDELINES
By Thursday, May 19, 2017, 5 p.m. please submit one PDF file (File name: Last name_V_Foundation_Peds.pdf) of the following via email attachment to:
Denise Baughman
Project Manager
Stanford Cancer Institute
deniseb@stanford.edu
Institutional representative: you do not have to submit your internal proposall through your RPM in RMG for their approval, you can submit it directly to Denise.
Exception: **CE faculty must obtain an approved CE faculty PI waiver request >> through their RPM at least one week prior to the internal deadline and include a copy with their internal proposal.)
1) One page page proposal:
Title of the RFP: V Foundation Pediatric Cancer Resesarch-Immunology or Immunotherapy
Project title:
Lead PI name, title, department, phone number and email
Co-PIs or Collaborators, if applicable (First and Last name, with degrees, instituton)
Please list your specific aims
Keywords*:
* The LOI will serve to identify specific areas of expertise for reviewer selection so please include relevant key words]
2) NIH Biosketch
3) For CE faculty only:
Please attach a copy of your approved CE faculty waiver request
For more information please click "Further Official Information" below.
This opportunity has expired. It was originally published here:
http://med.stanford.edu/rmg/funding/vfoundation_pediatric_ca.html